查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
欧洲细胞和基因治疗市场预测（2031年）-区域分析-按类型、服务、规模、服务提供者和最终用户
市场调查报告书
商品编码
1764843

欧洲细胞和基因治疗市场预测（2031年）-区域分析-按类型、服务、规模、服务提供者和最终用户

Europe Cell and Gene Therapy Market Forecast to 2031 - Regional Analysis - by Type, Services, Scale, Service Providers, and End User
出版日期: | 出版商: The Insight Partners | 英文 163 Pages | 订单完成后即时交付

价格

2023 年欧洲细胞和基因治疗市场价值为 11.051 亿美元，预计到 2031 年将达到 53.3444 亿美元；预计 2023 年至 2031 年的复合年增长率为 21.7%。

外包细胞和基因治疗製造的快速普及推动了欧洲细胞和基因治疗市场的发展

细胞和基因疗法的生产是一个复杂的过程，因此正确执行和监控操作至关重要。细胞和基因疗法製造商拥有精通生物和製程工程的合格人员数量有限。此外，对于经验丰富的团队来说，使用手动和开放式生产方法管理首次临床试验的尝试，以及建立更符合商业需求的流程，可能极具挑战性。因此，这些製造商选择与合约开发和生产组织 (CDMO) 合作，以加快其临床研究和商业化。 CDMO 以合约方式为细胞和基因疗法公司提供产品开发、生产、临床试验和商业化服务。与 CDMO 合作，细胞和基因疗法製造商能够实现可扩展性、加快上市速度、无需支付管理费用即可获得技术专业知识，并提高成本效益。事实证明，将细胞和基因疗法的生产外包给 CDMO 对製造商而言具有成本效益。他们可以获得 CDMO 先进的技术基础设施和专业知识。 CDMO 采用适当的、规划好的流程来生产细胞和基因疗法。因此，越来越倾向于将不断增长的细胞和基因治疗製造外包给 CDMO，这推动了欧洲细胞和基因治疗市场的成长。

欧洲细胞与基因治疗市场概况

由于对生产能力建设的投资、政府的大力支持以及对该地区的参与等因素，预计德国的细胞和基因治疗市场将在预测期内显着增长。此外，顶级竞争对手的存在将在预测期内增强区域市场的成长。德国拥有强大的製药业，特别注重研发。该国拥有 660 家生物技术公司，僱用了 50,000 名员工。其中，660 家公司专注于细胞和基因疗法 (CGT)。根据 NecstGen 的报告，2023 年有超过 29 项评估 CAR 修饰免疫细胞的活跃临床试验正在进行中，且大多数生产涉及 CAR-T 细胞。此外，到目前为止，德国已经在基因治疗领域进行了 50 多项临床研究。德国 CGT 公司的创新工作主要集中在地方或国家层面，因为它们缺乏国际影响力。

欧洲细胞和基因治疗市场收入及预测（2031年）（百万美元）

欧洲细胞和基因治疗市场细分

欧洲细胞和基因治疗市场分为类型、服务、规模、最终用户和国家。

根据类型，欧洲细胞和基因治疗市场分为细胞治疗和基因治疗。 2023年，细胞治疗占据了更大的市场。此外，细胞治疗细分市场又细分为同种异体载体、自体载体和病毒载体。基因治疗细分市场又细分为非病毒载体和病毒载体。

就服务而言，欧洲细胞和基因治疗市场分为製程开发、cGMP製造、监管服务和生物测定服务。製程开发领域在2023年占据了最大的市场。

依规模划分，欧洲细胞和基因治疗市场分为商业化前/研发生产和商业化规模生产。 2023年，商业化前/研发生产领域占据了更大的市场份额。

根据最终用户，欧洲细胞和基因治疗市场细分为合约研究组织、製药和生物製药公司以及学术和研究机构。製药和生物製药公司在2023年占据了最大的市场。

按国家/地区划分，欧洲细胞和基因治疗市场分为英国、德国、法国、义大利、西班牙和欧洲其他地区。 2023年，德国占据了欧洲细胞和基因治疗市场份额的主导地位。

Catalent Inc、Cell and Gene Therapy Catapult、Charles River Laboratories International Inc、F. Hoffmann-La Roche Ltd、FUJIFILM Holdings Corp、Lonza Group AG、Lotte Corp、Merck KGaA、Takara Bio Inc、Thermo Fisher Scientific Inc. 和无锡药明康德股份有限公司是一些欧洲细胞和基因治疗市场的领先公司。

目录

第一章：简介

第二章：执行摘要

  • 关键见解

第三章：研究方法

  • 二次研究
  • 初步研究
    • 假设表述：
    • 宏观经济因素分析：
    • 显影基数：
    • 数据三角测量：
    • 国家级资料：

第四章：欧洲细胞与基因治疗市场格局

  • 概述
  • PEST分析

第五章：欧洲细胞与基因治疗市场－关键市场动态

  • 细胞与基因治疗市场—关键市场动态
  • 市场驱动因素
    • 细胞和基因疗法获批数量的增加
    • 外包细胞与基因治疗製造迅速普及
  • 市场限制
    • 细胞和基因治疗製造成本高昂
  • 市场机会
    • 企业的策略倡议
  • 未来趋势
    • 细胞和基因治疗製造服务的自动化
  • 驱动因素和限制因素的影响：

第六章：细胞与基因治疗市场-欧洲市场分析

  • 欧洲概况
  • 2021-2031年欧洲细胞与基因治疗市场收入
  • 欧洲细胞和基因治疗市场预测分析

第七章：欧洲细胞与基因治疗市场分析－依类型

  • 细胞疗法
  • 基因治疗

第八章：欧洲细胞与基因治疗市场分析-按服务

  • 製程开发
  • cGMP 製造
  • 监管服务
  • 生物测定服务

第九章：欧洲细胞与基因治疗市场分析－依规模

  • 商业化前/研发製造
  • 商业规模生产

第 10 章：欧洲细胞和基因治疗市场分析 - 按服务提供者

  • 合约製造与生产组织
  • 首席行销长

第 11 章：欧洲细胞和基因治疗市场分析 - 按最终用户

  • 合约研究组织
  • 製药和生物製药公司
  • 学术和研究机构

第 12 章：欧洲细胞与基因治疗市场 - 国家分析

  • 英国
  • 德国
  • 法国
  • 义大利
  • 西班牙
  • 欧洲其他地区

第十三章：产业格局

  • 概述
  • 细胞和基因治疗市场的成长策略
  • 有机成长策略
    • 概述
  • 无机成长策略
    • 概述

第 14 章：公司简介

  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Charles River Laboratories International Inc
  • Cell and Gene Therapy Catapult
  • Lonza Group AG
  • WuXi AppTec Co Ltd
  • Takara Bio Inc
  • FUJIFILM Holdings Corp
  • F. Hoffmann-La Roche Ltd
  • Catalent Inc
  • Lotte Corp

第 15 章：附录

Product Code: BMIRE00031471

The Europe cell and gene therapy market was valued at US$ 1,105.10 million in 2023 and is projected to reach US$ 5,334.44 million by 2031; it is estimated to record a CAGR of 21.7% from 2023 to 2031.

Rapid Popularity of Outsourcing Cell and Gene Therapy Manufacturing Drives Europe Cell and Gene Therapy Market

Cell and gene therapy manufacturing is a complex process, which makes the proper execution and monitoring of the operation crucial. Cell and gene therapy manufacturers have a limited number of qualified personnel who know biological and process engineering. Moreover, for experienced teams, managing the attempts to reach the first clinical trial using a manual and open manufacturing method, as well as building a more commercially suitable process, can be challenging. Therefore, these manufacturers choose to work with contract development and manufacturing organizations (CDMOs) to accelerate their clinical studies and commercialization process. CDMOs support product development, manufacturing, clinical trials, and commercialization services to cell and gene therapy companies on a contract basis. Under the partnership with a CDMO, cell and gene therapy manufacturers support scalability, speed to market, access to technical expertise without overhead costs, and cost efficiencies. Outsourcing cell and gene therapy manufacturing to CDMOs proves to be cost-effective for manufacturers. They gain access to the technologically advanced infrastructure and expertise of CDMOs. CDMOs employ proper, mapped processes for manufacturing cell and gene therapies. Thus, the increasing preference for outsourcing growing cell and gene therapy manufacturing to CDMOs fuels the Europe cell and gene therapy market growth.

Europe Cell and Gene Therapy Market Overview

The cell and gene therapy market in Germany is expected to witness significant growth during the forecast period due to factors such as investment in the setup of production capacity, high government support, and involvement in the region. Also, the presence of top competitive players will enhance the regional market growth during the forecast period. Germany has a strong pharmaceutical industry with a notable focus on R&D. The country has 660 biotechnology companies that employ 50,000 employees. Among these, 660 companies are focused on cell and gene therapies (CGTs). As per the NecstGen report, more than 29 active clinical trials evaluating CAR-modified immune cells were ongoing in 2023, and most of the production involved CAR-T cells. Also, over 50 clinical studies have been conducted in gene therapy in Germany so far. The innovation efforts of German CGT companies are majorly focused on the local or country level, as they lack international presence.

Europe Cell and Gene Therapy Market Revenue and Forecast to 2031 (US$ Million)

Europe Cell and Gene Therapy Market Segmentation

The Europe cell and gene therapy market is categorized into type, services, scale, end user, and country.

Based on type, the Europe cell and gene therapy market is bifurcated into cell therapy and gene therapy. The cell therapy segment held a larger market share in 2023. Furthermore, the cell therapy segment is sub segmented into allogeneic, autologous, viral vectors. Additionally, the gene therapy segment is divided into non-viral vectors and viral vectors.

In terms of services, the Europe cell and gene therapy market is categorized process development, cGMP manufacturing, regulatory services, and bioassay services. The process development segment held the largest market share in 2023.

By scale, the Europe cell and gene therapy market is bifurcated into pre-commercial/R&D manufacturing and commercial scale manufacturing. The pre-commercial/R&D manufacturing segment held a larger market share in 2023.

Based on end user, the Europe cell and gene therapy market is segmented into contract research organizations, pharmaceutical and biopharmaceutical companies, and academic and research institutes. The pharmaceutical and biopharmaceutical companies segment held the largest market share in 2023.

By country, the Europe cell and gene therapy market is segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe. Germany dominated the Europe cell and gene therapy market share in 2023.

Catalent Inc, Cell and Gene Therapy Catapult, Charles River Laboratories International Inc, F. Hoffmann-La Roche Ltd, FUJIFILM Holdings Corp, Lonza Group AG, Lotte Corp, Merck KGaA, Takara Bio Inc, Thermo Fisher Scientific Inc., and WuXi AppTec Co Ltd are some of the leading companies operating in the Europe cell and gene therapy market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macro-economic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country level data:

4. Europe Cell and Gene Therapy Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis

5. Europe Cell and Gene Therapy Market - Key Market Dynamics

  • 5.1 Cell and Gene Therapy Market - Key Market Dynamics
  • 5.2 Market Drivers
    • 5.2.1 Increase in Number of Approval of Cell and Gene Therapies
    • 5.2.2 Rapid Popularity of Outsourcing Cell and Gene Therapy Manufacturing
  • 5.3 Market Restraints
    • 5.3.1 High Cost of Cell and Gene Therapy Manufacturing
  • 5.4 Market Opportunities
    • 5.4.1 Strategic Initiatives by Companies
  • 5.5 Future Trends
    • 5.5.1 Automation of Cell and Gene Therapy Manufacturing Services
  • 5.6 Impact of Drivers and Restraints:

6. Cell and Gene Therapy Market -Europe Market Analysis

  • 6.1 Overview Europe
  • 6.2 Europe Cell and Gene Therapy Market Revenue (US$ Million), 2021-2031
  • 6.3 Europe Cell and Gene Therapy Market Forecast Analysis

7. Europe Cell and Gene Therapy Market Analysis - by Type

  • 7.1 Cell Therapy
    • 7.1.1 Overview
    • 7.1.2 Cell Therapy: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.2 Gene Therapy
    • 7.2.1 Overview
    • 7.2.2 Gene Therapy: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)

8. Europe Cell and Gene Therapy Market Analysis - by Services

  • 8.1 Process Development
    • 8.1.1 Overview
    • 8.1.2 Process Development: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.2 cGMP Manufacturing
    • 8.2.1 Overview
    • 8.2.2 cGMP Manufacturing: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.3 Regulatory Services
    • 8.3.1 Overview
    • 8.3.2 Regulatory Services: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.4 Bioassay Services
    • 8.4.1 Overview
    • 8.4.2 Bioassay Services: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)

9. Europe Cell and Gene Therapy Market Analysis - by Scale

  • 9.1 Pre-Commercial/R&D Manufacturing
    • 9.1.1 Overview
    • 9.1.2 Pre-Commercial/R&D Manufacturing: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.2 Commercial Scale Manufacturing
    • 9.2.1 Overview
    • 9.2.2 Commercial Scale Manufacturing: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)

10. Europe Cell and Gene Therapy Market Analysis - by Service Providers

  • 10.1 CDMOs
    • 10.1.1 Overview
    • 10.1.2 CDMOs: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.2 CMOs
    • 10.2.1 Overview
    • 10.2.2 CMOs: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)

11. Europe Cell and Gene Therapy Market Analysis - by End User

  • 11.1 Contract Research Organizations
    • 11.1.1 Overview
    • 11.1.2 Contract Research Organizations: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  • 11.2 Pharmaceutical and Biopharmaceutical Companies
    • 11.2.1 Overview
    • 11.2.2 Pharmaceutical and Biopharmaceutical Companies: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  • 11.3 Academic and Research Institutes
    • 11.3.1 Overview
    • 11.3.2 Academic and Research Institutes: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)

12. Europe Cell and Gene Therapy Market - Country Analysis

  • 12.1 Europe Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
    • 12.1.1 Europe Cell and Gene Therapy Market - Revenue and Forecast Analysis - by Country
      • 12.1.1.1 Europe Cell and Gene Therapy Market - Revenue and Forecast Analysis - by Country
      • 12.1.1.2 United Kingdom: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
        • 12.1.1.2.1 United Kingdom: Cell and Gene Therapy Market Breakdown, by Type
          • 12.1.1.2.1.1 United Kingdom: Cell and Gene Therapy Market Breakdown, by Cell Therapy
          • 12.1.1.2.1.2 United Kingdom: Cell and Gene Therapy Market Breakdown, by Gene Therapy
        • 12.1.1.2.2 United Kingdom: Cell and Gene Therapy Market Breakdown, by Services
        • 12.1.1.2.3 United Kingdom: Cell and Gene Therapy Market Breakdown, by Scale
        • 12.1.1.2.4 United Kingdom: Cell and Gene Therapy Market Breakdown, by Service Providers
        • 12.1.1.2.5 United Kingdom: Cell and Gene Therapy Market Breakdown, by End User
      • 12.1.1.3 Germany: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
        • 12.1.1.3.1 Germany: Cell and Gene Therapy Market Breakdown, by Type
          • 12.1.1.3.1.1 Germany: Cell and Gene Therapy Market Breakdown, by Cell Therapy
          • 12.1.1.3.1.2 Germany: Cell and Gene Therapy Market Breakdown, by Gene Therapy
        • 12.1.1.3.2 Germany: Cell and Gene Therapy Market Breakdown, by Services
        • 12.1.1.3.3 Germany: Cell and Gene Therapy Market Breakdown, by Scale
        • 12.1.1.3.4 Germany: Cell and Gene Therapy Market Breakdown, by Service Providers
        • 12.1.1.3.5 Germany: Cell and Gene Therapy Market Breakdown, by End User
      • 12.1.1.4 France: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
        • 12.1.1.4.1 France: Cell and Gene Therapy Market Breakdown, by Type
          • 12.1.1.4.1.1 France: Cell and Gene Therapy Market Breakdown, by Cell Therapy
          • 12.1.1.4.1.2 France: Cell and Gene Therapy Market Breakdown, by Gene Therapy
        • 12.1.1.4.2 France: Cell and Gene Therapy Market Breakdown, by Services
        • 12.1.1.4.3 France: Cell and Gene Therapy Market Breakdown, by Scale
        • 12.1.1.4.4 France: Cell and Gene Therapy Market Breakdown, by Service Providers
        • 12.1.1.4.5 France: Cell and Gene Therapy Market Breakdown, by End User
      • 12.1.1.5 Italy: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
        • 12.1.1.5.1 Italy: Cell and Gene Therapy Market Breakdown, by Type
          • 12.1.1.5.1.1 Italy: Cell and Gene Therapy Market Breakdown, by Cell Therapy
          • 12.1.1.5.1.2 Italy: Cell and Gene Therapy Market Breakdown, by Gene Therapy
        • 12.1.1.5.2 Italy: Cell and Gene Therapy Market Breakdown, by Services
        • 12.1.1.5.3 Italy: Cell and Gene Therapy Market Breakdown, by Scale
        • 12.1.1.5.4 Italy: Cell and Gene Therapy Market Breakdown, by Service Providers
        • 12.1.1.5.5 Italy: Cell and Gene Therapy Market Breakdown, by End User
      • 12.1.1.6 Spain: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
        • 12.1.1.6.1 Spain: Cell and Gene Therapy Market Breakdown, by Type
          • 12.1.1.6.1.1 Spain: Cell and Gene Therapy Market Breakdown, by Cell Therapy
          • 12.1.1.6.1.2 Spain: Cell and Gene Therapy Market Breakdown, by Gene Therapy
        • 12.1.1.6.2 Spain: Cell and Gene Therapy Market Breakdown, by Services
        • 12.1.1.6.3 Spain: Cell and Gene Therapy Market Breakdown, by Scale
        • 12.1.1.6.4 Spain: Cell and Gene Therapy Market Breakdown, by Service Providers
        • 12.1.1.6.5 Spain: Cell and Gene Therapy Market Breakdown, by End User
      • 12.1.1.7 Rest of Europe: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
        • 12.1.1.7.1 Rest of Europe: Cell and Gene Therapy Market Breakdown, by Type
          • 12.1.1.7.1.1 Rest of Europe: Cell and Gene Therapy Market Breakdown, by Cell Therapy
          • 12.1.1.7.1.2 Rest of Europe: Cell and Gene Therapy Market Breakdown, by Gene Therapy
        • 12.1.1.7.2 Rest of Europe: Cell and Gene Therapy Market Breakdown, by Services
        • 12.1.1.7.3 Rest of Europe: Cell and Gene Therapy Market Breakdown, by Scale
        • 12.1.1.7.4 Rest of Europe: Cell and Gene Therapy Market Breakdown, by Service Providers
        • 12.1.1.7.5 Rest of Europe: Cell and Gene Therapy Market Breakdown, by End User

13. Industry Landscape

  • 13.1 Overview
  • 13.2 Growth Strategies in Cell and Gene Therapy Market
  • 13.3 Organic Growth Strategies
    • 13.3.1 Overview
  • 13.4 Inorganic Growth Strategies
    • 13.4.1 Overview

14. Company Profiles

  • 14.1 Thermo Fisher Scientific Inc.
    • 14.1.1 Key Facts
    • 14.1.2 Business Description
    • 14.1.3 Products and Services
    • 14.1.4 Financial Overview
    • 14.1.5 SWOT Analysis
    • 14.1.6 Key Developments
  • 14.2 Merck KGaA
    • 14.2.1 Key Facts
    • 14.2.2 Business Description
    • 14.2.3 Products and Services
    • 14.2.4 Financial Overview
    • 14.2.5 SWOT Analysis
    • 14.2.6 Key Developments
  • 14.3 Charles River Laboratories International Inc
    • 14.3.1 Key Facts
    • 14.3.2 Business Description
    • 14.3.3 Products and Services
    • 14.3.4 Financial Overview
    • 14.3.5 SWOT Analysis
    • 14.3.6 Key Developments
  • 14.4 Cell and Gene Therapy Catapult
    • 14.4.1 Key Facts
    • 14.4.2 Business Description
    • 14.4.3 Products and Services
    • 14.4.4 Financial Overview
    • 14.4.5 SWOT Analysis
    • 14.4.6 Key Developments
  • 14.5 Lonza Group AG
    • 14.5.1 Key Facts
    • 14.5.2 Business Description
    • 14.5.3 Products and Services
    • 14.5.4 Financial Overview
    • 14.5.5 SWOT Analysis
    • 14.5.6 Key Developments
  • 14.6 WuXi AppTec Co Ltd
    • 14.6.1 Key Facts
    • 14.6.2 Business Description
    • 14.6.3 Products and Services
    • 14.6.4 Financial Overview
    • 14.6.5 SWOT Analysis
    • 14.6.6 Key Developments
  • 14.7 Takara Bio Inc
    • 14.7.1 Key Facts
    • 14.7.2 Business Description
    • 14.7.3 Products and Services
    • 14.7.4 Financial Overview
    • 14.7.5 SWOT Analysis
    • 14.7.6 Key Developments
  • 14.8 FUJIFILM Holdings Corp
    • 14.8.1 Key Facts
    • 14.8.2 Business Description
    • 14.8.3 Products and Services
    • 14.8.4 Financial Overview
    • 14.8.5 SWOT Analysis
    • 14.8.6 Key Developments
  • 14.9 F. Hoffmann-La Roche Ltd
    • 14.9.1 Key Facts
    • 14.9.2 Business Description
    • 14.9.3 Products and Services
    • 14.9.4 Financial Overview
    • 14.9.5 SWOT Analysis
    • 14.9.6 Key Developments
  • 14.10 Catalent Inc
    • 14.10.1 Key Facts
    • 14.10.2 Business Description
    • 14.10.3 Products and Services
    • 14.10.4 Financial Overview
    • 14.10.5 SWOT Analysis
    • 14.10.6 Key Developments
  • 14.11 Lotte Corp
    • 14.11.1 Key Facts
    • 14.11.2 Business Description
    • 14.11.3 Products and Services
    • 14.11.4 Financial Overview
    • 14.11.5 SWOT Analysis
    • 14.11.6 Key Developments

15. Appendix

  • 15.1 About The Insight Partners
  • 15.2 Glossary of Terms

List Of Tables

  • Table 1. Cell and Gene Therapy Market Segmentation
  • Table 2. Europe Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  • Table 3. Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million) - by Type
  • Table 4. Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million) - by Cell Therapy
  • Table 5. Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million) - by Gene Therapy
  • Table 6. Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million) - by Services
  • Table 7. Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million) - by Scale
  • Table 8. Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million) - by Service Providers
  • Table 9. Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million) - by End User
  • Table 10. Europe: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Country
  • Table 11. United Kingdom: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 12. United Kingdom: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Cell Therapy
  • Table 13. United Kingdom: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Gene Therapy
  • Table 14. United Kingdom: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Services
  • Table 15. United Kingdom: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Scale
  • Table 16. United Kingdom: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Service Providers
  • Table 17. United Kingdom: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 18. Germany: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 19. Germany: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Cell Therapy
  • Table 20. Germany: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Gene Therapy
  • Table 21. Germany: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Services
  • Table 22. Germany: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Scale
  • Table 23. Germany: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Service Providers
  • Table 24. Germany: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 25. France: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 26. France: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Cell Therapy
  • Table 27. France: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Gene Therapy
  • Table 28. France: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Services
  • Table 29. France: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Scale
  • Table 30. France: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Service Providers
  • Table 31. France: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 32. Italy: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 33. Italy: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Cell Therapy
  • Table 34. Italy: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Gene Therapy
  • Table 35. Italy: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Services
  • Table 36. Italy: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Scale
  • Table 37. Italy: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Service Providers
  • Table 38. Italy: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 39. Spain: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 40. Spain: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Cell Therapy
  • Table 41. Spain: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Gene Therapy
  • Table 42. Spain: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Services
  • Table 43. Spain: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Scale
  • Table 44. Spain: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Service Providers
  • Table 45. Spain: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 46. Rest of Europe: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 47. Rest of Europe: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Cell Therapy
  • Table 48. Rest of Europe: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Gene Therapy
  • Table 49. Rest of Europe: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Services
  • Table 50. Rest of Europe: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Scale
  • Table 51. Rest of Europe: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Service Providers
  • Table 52. Rest of Europe: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 53. Recent Organic Growth Strategies in Cell and Gene Therapy Market
  • Table 54. Recent Inorganic Growth Strategies in the Cell and Gene Therapy Market
  • Table 55. Glossary of Terms

List Of Figures

  • Figure 1. Cell and Gene Therapy Market Segmentation, by Country
  • Figure 2. PEST Analysis
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Europe Cell and Gene Therapy Market Revenue (US$ Million), 2021-2031
  • Figure 5. Cell and Gene Therapy Market Share (%) - by Type (2023 and 2031)
  • Figure 6. Cell Therapy: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 7. Gene Therapy: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 8. Cell and Gene Therapy Market Share (%) - by Services (2023 and 2031)
  • Figure 9. Process Development: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 10. cGMP Manufacturing: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 11. Regulatory Services: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 12. Bioassay Services: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 13. Cell and Gene Therapy Market Share (%) - by Scale (2023 and 2031)
  • Figure 14. Pre-Commercial/R&D Manufacturing: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 15. Commercial Scale Manufacturing: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 16. Cell and Gene Therapy Market Share (%) - by Service Providers (2023 and 2031)
  • Figure 17. CDMOs: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 18. CMOs: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 19. Cell and Gene Therapy Market Share (%) - by End User (2023 and 2031)
  • Figure 20. Contract Research Organizations: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 21. Pharmaceutical and Biopharmaceutical Companies: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 22. Academic and Research Institutes: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 23. Europe Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 24. Europe Cell and Gene Therapy Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 25. United Kingdom: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 26. Germany: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 27. France: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 28. Italy: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 29. Spain: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 30. Rest of Europe: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 31. Growth Strategies in Cell and Gene Therapy Market